200 related articles for article (PubMed ID: 11917943)
21. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma.
Legha SS; Ring S; Papadopoulos N; Plager C; Chawla S; Benjamin R
Cancer; 1989 Nov; 64(10):2024-9. PubMed ID: 2804890
[TBL] [Abstract][Full Text] [Related]
22. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
Luikart SD; Kennealey GT; Kirkwood JM
J Clin Oncol; 1984 Mar; 2(3):164-8. PubMed ID: 6199481
[TBL] [Abstract][Full Text] [Related]
24. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
[TBL] [Abstract][Full Text] [Related]
25. Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Bafaloukos D; Aravantinos G; Fountzilas G; Stathopoulos G; Gogas H; Samonis G; Briasoulis E; Mylonakis N; Skarlos DV; Kosmidis P
Oncology; 2002; 63(4):333-7. PubMed ID: 12417787
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
[TBL] [Abstract][Full Text] [Related]
28. Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H; Bafaloukos D; Aravantinos G; Fountzilas G; Tsoutsos D; Panagiotou P; Frangia K; Kalofonos HP; Briasoulis E; Castana O; Polyzos A; Pectasides D; Ioannovich J;
Cancer Invest; 2004; 22(6):832-9. PubMed ID: 15641480
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
30. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
31. Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma.
Bajetta E; Rimassa L; Carnaghi C; Del Vecchio M; Celio L; Cassata A
Tumori; 1998; 84(1):48-51. PubMed ID: 9619714
[TBL] [Abstract][Full Text] [Related]
32. Combined carboplatin and cytosine arabinoside in metastatic melanoma refractory to dacarbazine.
Bajetta E; Buzzoni R; Vicario G
Tumori; 1995; 81(4):238-40. PubMed ID: 8540118
[TBL] [Abstract][Full Text] [Related]
33. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
35. A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma.
Schachter J; Rakowsky E; Sulkes A; Adler A
Cancer Biother Radiopharm; 1998 Jun; 13(3):155-64. PubMed ID: 10850351
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
37. [Clinical evaluation of the efficacy of modern first, second, and third line regimes of chemotherapy in patients with disseminated cutaneous melanoma].
Akimov MA; Gershanovich ML
Vopr Onkol; 2001; 47(4):428-35. PubMed ID: 11710284
[TBL] [Abstract][Full Text] [Related]
38. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
Tarhini AA; Kirkwood JM; Gooding WE; Cai C; Agarwala SS
J Clin Oncol; 2007 Sep; 25(25):3802-7. PubMed ID: 17761969
[TBL] [Abstract][Full Text] [Related]
39. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
40. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]